179 related articles for article (PubMed ID: 31084551)
1. Bone-Marrow Suppression in Elderly Patients Following Empiric Radioiodine Therapy: Real-Life Data.
Duskin-Bitan H; Leibner A; Amitai O; Diker-Cohen T; Hirsch D; Benbassat C; Shimon I; Robenshtok E
Thyroid; 2019 May; 29(5):683-691. PubMed ID: 31084551
[No Abstract] [Full Text] [Related]
2. Bone marrow suppression in pediatric patients with differentiated thyroid cancer following empirical radioiodine therapy.
Dong P; Wang L; Huang R; Li L
Medicine (Baltimore); 2020 Jul; 99(31):e21398. PubMed ID: 32756134
[TBL] [Abstract][Full Text] [Related]
3. Short-term bone marrow suppression in differentiated thyroid cancer patients after radioactive iodine treatment.
Yi W; Kim BH; Kim M; Ryang SR; Jang MH; Kim JM; Kim EH; Jeon YK; Kim SS; Kim IJ
Endocr J; 2020 Dec; 67(12):1193-1198. PubMed ID: 32727965
[TBL] [Abstract][Full Text] [Related]
4. Mild decreases in white blood cell and platelet counts are present one year after radioactive iodine remnant ablation.
Molinaro E; Leboeuf R; Shue B; Martorella AJ; Fleisher M; Larson S; Tuttle RM
Thyroid; 2009 Oct; 19(10):1035-41. PubMed ID: 19772430
[TBL] [Abstract][Full Text] [Related]
5. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer.
Tuttle RM; Leboeuf R; Robbins RJ; Qualey R; Pentlow K; Larson SM; Chan CY
J Nucl Med; 2006 Oct; 47(10):1587-91. PubMed ID: 17015892
[TBL] [Abstract][Full Text] [Related]
6. Absence of bone marrow toxicity in elderly patients treated with recombinant human thyroid-stimulating hormone and empirically dosed radioiodine for thyroid cancer.
Amdur RJ; Dan T; Mazzaferri E
Am J Clin Oncol; 2013 Aug; 36(4):348-53. PubMed ID: 22547013
[TBL] [Abstract][Full Text] [Related]
7. Complete blood counts are frequently abnormal 1 year after dosimetry-guided radioactive iodine therapy for metastatic thyroid cancer.
Padovani RP; Tuttle RM; Grewal R; Larson SM; Boucai L
Endocr Pract; 2014 Mar; 20(3):213-20. PubMed ID: 24126230
[TBL] [Abstract][Full Text] [Related]
8. Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial.
Kiyota N; Robinson B; Shah M; Hoff AO; Taylor MH; Li D; Dutcus CE; Lee EK; Kim SB; Tahara M
Thyroid; 2017 Sep; 27(9):1135-1141. PubMed ID: 28665259
[TBL] [Abstract][Full Text] [Related]
9. The effect of radioiodine therapy on blood cell count in patients with differentiated thyroid cancer.
Demir AN; Kara Z; Sulu C; Uysal S; Zulfaliyeva G; Atar OA; Valikhanova N; Ozturk T; Ozkaya HM; Damci T; Gonen MS
Hormones (Athens); 2023 Dec; 22(4):595-602. PubMed ID: 37603221
[TBL] [Abstract][Full Text] [Related]
10. Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer.
de Keizer B; Hoekstra A; Konijnenberg MW; de Vos F; Lambert B; van Rijk PP; Lips CJ; de Klerk JM
J Nucl Med; 2004 Sep; 45(9):1549-54. PubMed ID: 15347723
[TBL] [Abstract][Full Text] [Related]
11. Incidence of Nonthyroidal Primary Malignancy and the Association with (131)I Treatment in Patients with Differentiated Thyroid Cancer.
Hirsch D; Shohat T; Gorshtein A; Robenshtok E; Shimon I; Benbassat C
Thyroid; 2016 Aug; 26(8):1110-6. PubMed ID: 27302111
[TBL] [Abstract][Full Text] [Related]
12. Influence of the first radioactive iodine ablation on peripheral complete blood count in patients with differentiated thyroid cancer.
Hu T; Meng Z; Zhang G; Jia Q; Tan J; Zheng W; Wang R; Li X; Liu N; Zhou P; Upadhyaya A
Medicine (Baltimore); 2016 Aug; 95(35):e4451. PubMed ID: 27583853
[TBL] [Abstract][Full Text] [Related]
13. Assessment of three different radioiodine doses for ablation therapy of thyroid remnants: Efficiency, complications and patient comfort.
Soyluoglu S; Andac B; Korkmaz U; Ustun F
Medicine (Baltimore); 2023 Sep; 102(39):e35339. PubMed ID: 37773808
[TBL] [Abstract][Full Text] [Related]
14. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach.
Dorn R; Kopp J; Vogt H; Heidenreich P; Carroll RG; Gulec SA
J Nucl Med; 2003 Mar; 44(3):451-6. PubMed ID: 12621014
[TBL] [Abstract][Full Text] [Related]
15. Influence of radioactive iodine therapy on liver function in patients with differentiated thyroid cancer.
Wang S; Liang C; Zhao L; Meng Z; Zhang C; Jia Q; Tan J; Yang H; Liu X; Wang X
Nucl Med Commun; 2018 Dec; 39(12):1113-1120. PubMed ID: 30247387
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal Analysis of the Effect of Radioiodine Therapy on Ovarian Reserve in Females with Differentiated Thyroid Cancer.
van Velsen EFS; Visser WE; van den Berg SAA; Kam BLR; van Ginhoven TM; Massolt ET; Peeters RP
Thyroid; 2020 Apr; 30(4):580-587. PubMed ID: 31928168
[No Abstract] [Full Text] [Related]
17. Differentiated Thyroid Cancer lymph-node relapse. Role of adjuvant radioactive iodine therapy after lymphadenectomy.
Piccardo A; Puntoni M; Bottoni G; Treglia G; Foppiani L; Bertoli M; Catrambone U; Arlandini A; Dib B; Altrinetti V; Massollo M; Bossert I; Cabria M; Bertagna F; Giovanella L
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):926-934. PubMed ID: 27966046
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes of low-dose and high-dose postoperative radioiodine therapy in patients with intermediate-risk differentiated thyroid cancer.
Jeong JH; Kong EJ; Jeong SY; Lee SW; Cho IH; Ah Chun K; Lee J; Ahn BC
Nucl Med Commun; 2017 Mar; 38(3):228-233. PubMed ID: 27984538
[TBL] [Abstract][Full Text] [Related]
19. Effect of ¹³¹I Therapy on Complete Blood Count in Patients with Differentiated Thyroid Cancer.
Rui Z; Wu R; Zheng W; Wang X; Meng Z; Tan J
Med Sci Monit; 2021 Feb; 27():e929590. PubMed ID: 33568620
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes following empiric radioiodine therapy in patients with structurally identifiable metastatic follicular cell-derived thyroid carcinoma with negative diagnostic but positive post-therapy 131I whole-body scans.
Sabra MM; Grewal RK; Tala H; Larson SM; Tuttle RM
Thyroid; 2012 Sep; 22(9):877-83. PubMed ID: 22827641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
